Literature DB >> 24882515

Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.

Xiaodong Feng1, Maria Sol Degese2, Ramiro Iglesias-Bartolome2, Jose P Vaque2, Alfredo A Molinolo2, Murilo Rodrigues3, M Raza Zaidi4, Bruce R Ksander5, Glenn Merlino6, Akrit Sodhi3, Qianming Chen7, J Silvio Gutkind8.   

Abstract

Mutually exclusive activating mutations in the GNAQ and GNA11 oncogenes, encoding heterotrimeric Gαq family members, have been identified in ∼ 83% and ∼ 6% of uveal and skin melanomas, respectively. However, the molecular events underlying these GNAQ-driven malignancies are not yet defined, thus limiting the ability to develop cancer-targeted therapies. Here, we focused on the transcriptional coactivator YAP, a critical component of the Hippo signaling pathway that controls organ size. We found that Gαq stimulates YAP through a Trio-Rho/Rac signaling circuitry promoting actin polymerization, independently of phospholipase Cβ and the canonical Hippo pathway. Furthermore, we show that Gαq promotes the YAP-dependent growth of uveal melanoma cells, thereby identifying YAP as a suitable therapeutic target in uveal melanoma, a GNAQ/GNA11-initiated human malignancy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24882515      PMCID: PMC4074519          DOI: 10.1016/j.ccr.2014.04.016

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  56 in total

Review 1.  Ras and Rho GTPases: a family reunion.

Authors:  D Bar-Sagi; A Hall
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  Photodynamic therapy with verteporfin: a new treatment in ophthalmology.

Authors:  S Michels; U Schmidt-Erfurth
Journal:  Semin Ophthalmol       Date:  2001-12       Impact factor: 1.975

3.  Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.

Authors:  P A van der Velden; J A Metzelaar-Blok; W Bergman; H Monique; H Hurks; R R Frants; N A Gruis; M J Jager
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

4.  Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.

Authors:  Bin Zhao; Li Li; Qing Lu; Lloyd H Wang; Chen-Ying Liu; Qunying Lei; Kun-Liang Guan
Journal:  Genes Dev       Date:  2011-01-01       Impact factor: 11.361

5.  Mutations in GNA11 in uveal melanoma.

Authors:  Catherine D Van Raamsdonk; Klaus G Griewank; Michelle B Crosby; Maria C Garrido; Swapna Vemula; Thomas Wiesner; Anna C Obenauf; Werner Wackernagel; Gary Green; Nancy Bouvier; M Mert Sozen; Gail Baimukanova; Ritu Roy; Adriana Heguy; Igor Dolgalev; Raya Khanin; Klaus Busam; Michael R Speicher; Joan O'Brien; Boris C Bastian
Journal:  N Engl J Med       Date:  2010-11-17       Impact factor: 91.245

6.  Diverse somatic mutation patterns and pathway alterations in human cancers.

Authors:  Zhengyan Kan; Bijay S Jaiswal; Jeremy Stinson; Vasantharajan Janakiraman; Deepali Bhatt; Howard M Stern; Peng Yue; Peter M Haverty; Richard Bourgon; Jianbiao Zheng; Martin Moorhead; Subhra Chaudhuri; Lynn P Tomsho; Brock A Peters; Kanan Pujara; Shaun Cordes; David P Davis; Victoria E H Carlton; Wenlin Yuan; Li Li; Weiru Wang; Charles Eigenbrot; Joshua S Kaminker; David A Eberhard; Paul Waring; Stephan C Schuster; Zora Modrusan; Zemin Zhang; David Stokoe; Frederic J de Sauvage; Malek Faham; Somasekar Seshagiri
Journal:  Nature       Date:  2010-07-28       Impact factor: 49.962

7.  Treatment of choroidal melanoma using photodynamic therapy.

Authors:  Irene A Barbazetto; Thomas C Lee; Indira S Rollins; Stanley Chang; David H Abramson
Journal:  Am J Ophthalmol       Date:  2003-06       Impact factor: 5.258

8.  An evolutionary shift in the regulation of the Hippo pathway between mice and flies.

Authors:  W Bossuyt; C-L Chen; Q Chen; M Sudol; H McNeill; D Pan; A Kopp; G Halder
Journal:  Oncogene       Date:  2013-04-08       Impact factor: 9.867

Review 9.  The hippo signaling pathway in development and cancer.

Authors:  Duojia Pan
Journal:  Dev Cell       Date:  2010-10-19       Impact factor: 12.270

10.  Interferon-γ links ultraviolet radiation to melanomagenesis in mice.

Authors:  M Raza Zaidi; Sean Davis; Frances P Noonan; Cari Graff-Cherry; Teresa S Hawley; Robert L Walker; Lionel Feigenbaum; Elaine Fuchs; Lyudmila Lyakh; Howard A Young; Thomas J Hornyak; Heinz Arnheiter; Giorgio Trinchieri; Paul S Meltzer; Edward C De Fabo; Glenn Merlino
Journal:  Nature       Date:  2011-01-19       Impact factor: 49.962

View more
  222 in total

Review 1.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.

Authors:  Anwesha Dey; Xaralabos Varelas; Kun-Liang Guan
Journal:  Nat Rev Drug Discov       Date:  2020-06-17       Impact factor: 84.694

2.  Alternative Wnt Signaling Activates YAP/TAZ.

Authors:  Hyun Woo Park; Young Chul Kim; Bo Yu; Toshiro Moroishi; Jung-Soon Mo; Steven W Plouffe; Zhipeng Meng; Kimberly C Lin; Fa-Xing Yu; Caroline M Alexander; Cun-Yu Wang; Kun-Liang Guan
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

3.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Authors:  Luping Lin; Amit J Sabnis; Elton Chan; Victor Olivas; Lindsay Cade; Evangelos Pazarentzos; Saurabh Asthana; Dana Neel; Jenny Jiacheng Yan; Xinyuan Lu; Luu Pham; Mingxue M Wang; Niki Karachaliou; Maria Gonzalez Cao; Jose Luis Manzano; Jose Luis Ramirez; Jose Miguel Sanchez Torres; Fiamma Buttitta; Charles M Rudin; Eric A Collisson; Alain Algazi; Eric Robinson; Iman Osman; Eva Muñoz-Couselo; Javier Cortes; Dennie T Frederick; Zachary A Cooper; Martin McMahon; Antonio Marchetti; Rafael Rosell; Keith T Flaherty; Jennifer A Wargo; Trever G Bivona
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

4.  HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Authors:  Fernanda Faião-Flores; Michael F Emmons; Michael A Durante; Fumi Kinose; Biswarup Saha; Bin Fang; John M Koomen; Srikumar P Chellappan; Silvya Stuchi Maria-Engler; Uwe Rix; Jonathan D Licht; J William Harbour; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

5.  Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation.

Authors:  Ya-Wen Ma; Yi-Zhi Liu; Jing-Xuan Pan
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

Review 6.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

7.  Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Authors:  Jonathan W Haskins; Don X Nguyen; David F Stern
Journal:  Sci Signal       Date:  2014-12-09       Impact factor: 8.192

8.  Atypical activation of the G protein Gαq by the oncogenic mutation Q209P.

Authors:  Marcin Maziarz; Anthony Leyme; Arthur Marivin; Alex Luebbers; Prachi P Patel; Zhe Chen; Stephen R Sprang; Mikel Garcia-Marcos
Journal:  J Biol Chem       Date:  2018-10-23       Impact factor: 5.157

9.  GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?

Authors:  Matthew G Field; J William Harbour
Journal:  Cancer Cell       Date:  2014-06-16       Impact factor: 31.743

10.  The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.

Authors:  Carsten Gram Hansen; Yuen Lam Dora Ng; Wai-Ling Macrina Lam; Steven W Plouffe; Kun-Liang Guan
Journal:  Cell Res       Date:  2015-11-27       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.